logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10363253 B1

PDFFull Text
Date of Patent:
Jul. 30, 2019

Filed:

Feb. 02, 2017

Combination products for the treatment of rsv

Applicant:

Janssen Sciences Ireland Unlimited Company, County Cork, IE;

Inventors:

Nina Ysebaert, Beerse, BE;

Nele Isa E. Goeyvaerts, Beerse, BE;

Dirk André E. Roymans, Beerse, BE;

Anil Koul, Beerse, BE;

Assignee:

Janssen Sciences Ireland Unlimited Company, Ringaskiddy, Co Cork, IE;

Attorney:
Primary Examiner:

Yong L Chu

Int. Cl.
CPC ...
A61K 31/496 (2006.01); A61K 31/7056 (2006.01); A61K 31/519 (2006.01); A61K 31/41 (2006.01); A61K 39/42 (2006.01); A61K 31/55 (2006.01); A61K 31/4745 (2006.01); A61P 31/14 (2006.01); A61K 31/4184 (2006.01); A61K 31/437 (2006.01); A61K 31/52 (2006.01); A61K 31/53 (2006.01); A61K 31/5377 (2006.01); A61K 31/5513 (2006.01); A61K 31/70 (2006.01); C07K 16/10 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/496 (2013.01); A61K 31/41 (2013.01); A61K 31/4184 (2013.01); A61K 31/437 (2013.01); A61K 31/4745 (2013.01); A61K 31/519 (2013.01); A61K 31/52 (2013.01); A61K 31/53 (2013.01); A61K 31/5377 (2013.01); A61K 31/55 (2013.01); A61K 31/5513 (2013.01); A61K 31/70 (2013.01); A61K 31/7056 (2013.01); A61K 39/42 (2013.01); A61P 31/14 (2018.01); C07K 16/10 (2013.01); C07K 16/1027 (2013.01); A61K 39/395 (2013.01); A61K 2039/505 (2013.01);
Abstract

The present invention is directed to the combination of the RSV inhibiting Compound A, i.e. 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl) 1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and one or more RSV inhibiting Compound B selected from from ribavirin, GS-5806, MDT-637, BTA-9881, BMS-433771, YM-543403, A-60444, TMC-353121, RFI-641, CL-387626, MBX-300, AZ-27, MEDI8897, CR9501, palivizumab, 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl}methyl)-1 cyclopropyl-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, 3-[[7-chloro-3-(2 ethyl-sulfonylethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-1-cyclopropyl-imidazo[4,5-c]pyridin-2 one, N-(2-fluoro-6-methylphenyl)-6-(4-(5-methyl-2-(7-oxa-2-azaspiro[3.5]nonan-2 yl)nicotinamido)benzoyl)-5,6-dihydro-4H-benzo[b]thieno[2,3-d]azepine-2-carboxamide, and 4-amino-8-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-6,6-dimethyl-2-(4-methyl 3-nitrophenyl)-3H-imidazo[4,5-h]isoquinoline-7,9(6H,8H)-dione, for treating or ameliorating RSV infection. The invention further relates to the combination product of Compound A and one or more Compound B, a pharmaceutical product comprising Compound A and one or more Compound B, the use of the combination of Compound A and one or more of Compound B—or the pharmaceutical product comprising Compound A and one or more Compound B—for the treatment of RSV infection, and a method of treating or ameliorating RSV infection in a subject in need thereof comprising administering the combination of Compound A and one or more Compound B in an effective amount to said subject.

Find Patent Forward Citations

Loading…